Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
about
Nutritional modulation of endogenous glucagon-like peptide-1 secretion: a reviewRecent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsPeripheral signals mediate the beneficial effects of gastric surgery in obesitySurgical treatment of type 2 diabetes: the surgeon perspective.Obesity may attenuate the HbA1c-lowering effect of sitagliptin in Japanese type 2 diabetic patients.Prevention of obesity-induced renal injury in male mice by DPP4 inhibition.Abscisic Acid: A Novel Nutraceutical for Glycemic Control.DPP4 inhibition attenuates filtration barrier injury and oxidant stress in the zucker obese ratCould the improvement of obesity-related co-morbidities depend on modified gut hormones secretion?Impaired increase of plasma abscisic Acid in response to oral glucose load in type 2 diabetes and in gestational diabetesMechanisms responsible for excess weight loss after bariatric surgeryGastrointestinal hormones and bariatric surgery-induced weight lossChronic high-fat feeding increases GIP and GLP-1 secretion without altering body weightHigher BNP levels within physiological range correlate with beneficial nonfasting lipid profiles in the elderly: a cross-sectional studyGastric bypass surgery, but not caloric restriction, decreases dipeptidyl peptidase-4 activity in obese patients with type 2 diabetes.Plasma dipeptidyl peptidase IV activity and measures of body composition in apparently healthy people.Nutrient-specific feeding and endocrine effects of jejunal infusions in obese animals.Metabolic surgery-principles and current concepts.Ghrelin, CCK, GLP-1, and PYY(3-36): Secretory Controls and Physiological Roles in Eating and Glycemia in Health, Obesity, and After RYGB.The contributions of dipeptidyl peptidase IV to inflammation in heart failure.GLP-1 and peptide YY secretory response after fat load is impaired by insulin resistance, impaired fasting glucose and type 2 diabetes in morbidly obese subjects.Butyrylcholinesterase and γ-glutamyltransferase activities and oxidative stress markers are altered in metabolic syndrome, but are not affected by body mass index.Nutrient-stimulated glucagon-like peptide 1 release after body-weight loss and weight maintenance in human subjects.Altered Appetite-Mediating Hormone Concentrations Precede Compensatory Overeating After Severe, Short-Term Energy Deprivation in Healthy Adults.Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes.Postprandial GLP-2 Levels Are Increased After Biliopancreatic Diversion in Diabetic Individuals with Class I Obesity: a Prospective Study.Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal.Basal GLP-1 levels in morbidly obese patients following biliopancreatic diversion surgery.Ghrelin does not influence gastric emptying in obese subjects.
P2860
Q28070256-CAF6524D-E938-42C9-86E6-7CBA980BFE72Q28081569-C65804D9-28EC-4C08-91F1-A4D2ABF1CBFCQ28088425-E7143FF3-88EC-42D9-B222-165DB78D4AF3Q30405974-0E512853-CBB7-4B14-A52C-293D7A8919BBQ33609811-92BE76EC-580D-4954-A87E-4A5235759683Q33610654-2E581390-5C2F-4874-B350-7EE30CB860FFQ33790397-8D348E69-0EB6-4C1C-BC5A-E32100428B2FQ34270500-D7715F59-A867-4FB7-ADEC-5B5BF2E60FC4Q34589770-A161310B-A98E-487C-AA58-A41B28AD620DQ35130462-069FDC9E-9B91-47BD-BCE9-9ABD144741D8Q35529693-8D420AD2-19ED-4DA5-A1D2-CEF95AF46F13Q35581251-0983E477-ADB2-4E0A-B82B-305520027890Q36297735-4ABACBD7-AEBC-4909-8D8B-5378F37CD4EBQ36428904-FF41F52C-7605-45FB-B7E3-96EB2693F340Q36850966-22F901E2-D4F4-40D1-81B1-59B18D6CA2ADQ37096820-53FB5FC1-F3A5-4569-91D6-1B7048A04B87Q37629367-AEDCCB11-980F-4E0D-AB8D-B5909C59B799Q37922651-8CCC4643-5355-4450-9A8E-BDE511456891Q39047697-2700B203-37EF-47C8-8A00-FA7D672478D4Q39751432-586270DE-5CB9-4661-B5F7-2C309128600BQ45066824-BF0BA3B4-AF48-49CB-9E2E-849237152540Q45086975-4CFB1DF2-A495-4705-869D-0938BADE40D8Q46915426-657C4D80-32D4-4482-AB3A-5998256B2114Q47582484-D40F43E4-211E-4075-BF5C-F0178C34AE4DQ47603611-B2297148-358F-45EB-B542-E6D63B8AEB17Q48336786-65955528-EB1D-475B-B35D-39EA85B1A5F7Q50445809-C4ED68A5-FAA4-49C2-837A-56C0DD4EC9EDQ51353310-7E708EC3-48D3-477B-BA99-FBFE1553A135Q51517195-9FEB56B3-7306-46E0-8455-DFBA097E1708
P2860
Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Glucagon-like peptide 1 (GLP-1 ...... ing biliopancreatic diversion.
@en
type
label
Glucagon-like peptide 1 (GLP-1 ...... ing biliopancreatic diversion.
@en
prefLabel
Glucagon-like peptide 1 (GLP-1 ...... ing biliopancreatic diversion.
@en
P2093
P356
P1476
Glucagon-like peptide 1 (GLP-1 ...... ing biliopancreatic diversion.
@en
P2093
Barilli AL
Camellini C
Ganzerla GC
Mittenperger F
P304
P356
10.1055/S-2004-814222
P577
2004-02-01T00:00:00Z